![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ABBOTT RECEIVES FDA APPROVAL FOR NEW HUMIRA DELIVERY DEVICE
ABBOTT RECEIVES FDA APPROVAL FOR NEW HUMIRA DELIVERY DEVICE
June 27, 2006
Abbott announced today that the U.S. Food and Drug Administration (FDA) approved the HUMIRA Pen, a new device for administering HUMIRA (adalimumab), a treatment approved for moderate to severe rheumatoid arthritis (RA) and psoriatic arthritis (PsA). With its one-touch activation and easy-to-grasp size and shape, the HUMIRA Pen offers improved ease of use for these patients, many of whom may have swelling or stiffness in the hands.
Abbott Laboratories
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct